Abstract
ObjectiveThe prognostic value of vimentin expression in Gastric Cancer (GC) has been assessed for years while the results are still in dispute. Thus, we performed a meta-analysis to determine the effect of vimentin immunohistochemical (IHC) expression on the prognosis of GC. MethodsLiterature searches were performed in PubMed and Embase. The meta-analysis examined the association of vimentin IHC expression with prognosis and clinicopathological characteristics of GC patients. ResultsIn total, ten studies involving 1598 cases were enrolled in this meta-analysis. Vimentin positive expression was significantly correlated with poor overall survival (OS) in GC patients (HR = 2.05, 95% CI: 1.29–3.24) but there was a significant degree of heterogeneity (I2 = 77%, P = 0.0006). Subgroup analysis indicated that vimentin expression had an unfavorable impact on OS in Chinese patients (HR = 2.43, 95% CI: 1.30–4.55). Moreover, vimentin positive expression rates was significantly associated with age, tumor location, TNM stage and lymph node metastasis. However, vimentin positive expression rates did not correlate with gender, grade of differentiation, vascular invasion, the depth of invasion, hepatic metastasis or peritoneal metastasis. ConclusionsPositive vimentin expression could serve as a poor prognostic marker in GC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
